Coenzyme M

Generic Name
Coenzyme M
Brand Names
Uromitexan
Drug Type
Small Molecule
Chemical Formula
C2H6O3S2
CAS Number
3375-50-6
Unique Ingredient Identifier
VHD28S0H7F
Background

Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Indication

Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.

Associated Conditions
Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Associated Therapies
-
Clinical Trials
Related News

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2004-08-11
Last Posted Date
2018-08-10
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
25
Registration Number
NCT00002865
Locations
🇺🇸

Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

First Posted Date
2004-07-29
Last Posted Date
2013-04-04
Lead Sponsor
ETOP IBCSG Partners Foundation
Target Recruit Count
344
Registration Number
NCT00002784
Locations
🇦🇺

Queen Elizabeth Hospital, Adelaide, South Australia, Australia

🇦🇺

Royal Prince Alfred Hospital, Sydney, Sydney, New South Wales, Australia

🇦🇺

Royal Adelaide Hospital, Adelaide, South Australia, Australia

and more 8 locations

Chemotherapy in Treating Patients With Retinoblastoma

Phase 2
Completed
Conditions
Retinoblastoma
First Posted Date
2004-07-29
Last Posted Date
2013-06-28
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
50
Registration Number
NCT00002675
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer

Phase 1
Conditions
Breast Cancer
First Posted Date
2004-07-29
Last Posted Date
2014-01-10
Lead Sponsor
St. Louis University
Target Recruit Count
30
Registration Number
NCT00002627
Locations
🇺🇸

St. Louis University Health Sciences Center, Saint Louis, Missouri, United States

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Phase 3
Conditions
Leukemia
First Posted Date
2004-07-19
Last Posted Date
2009-12-23
Lead Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Target Recruit Count
1520
Registration Number
NCT00002549
Locations
🇵🇹

Hospitais da Universidade de Coimbra (HUC), Coimbra, Portugal

🇨🇿

Institute of Hematology and Blood Transfusion, Prague, Czech Republic

🇧🇪

Algemeen Ziekenhuis Middelheim, Antwerp, Belgium

and more 72 locations

Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Lymphoma
First Posted Date
2004-07-01
Last Posted Date
2013-06-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Registration Number
NCT00002691
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Radiation Therapy and Chemotherapy in Treating Children With CNS Relapse From Acute Lymphoblastic Leukemia

First Posted Date
2004-07-01
Last Posted Date
2013-02-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
156
Registration Number
NCT00002704
Locations
🇺🇸

West Virginia University Hospitals, Morgantown, West Virginia, United States

🇺🇸

Emory University Hospital - Atlanta, Atlanta, Georgia, United States

🇺🇸

Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

and more 67 locations

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Children With Advanced Soft Tissue Sarcoma

First Posted Date
2004-07-01
Last Posted Date
2014-07-25
Lead Sponsor
Children's Oncology Group
Target Recruit Count
43
Registration Number
NCT00002804
Locations
🇺🇸

Via Christi Regional Medical Center, Wichita, Kansas, United States

🇺🇸

MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States

🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

and more 6 locations

Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma

First Posted Date
2004-06-30
Last Posted Date
2018-11-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
61
Registration Number
NCT00002565
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

🇧🇷

Faculdade de Medicina do ABC, Sao Paulo, Brazil

🇨🇱

Clinica Alemana, Santiago, Chile

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

First Posted Date
2004-06-23
Last Posted Date
2013-08-22
Lead Sponsor
Children's Oncology Group
Target Recruit Count
120
Registration Number
NCT00002816
Locations
🇺🇸

Children's National Medical Center, Washington, District of Columbia, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

🇺🇸

Kaplan Cancer Center, New York, New York, United States

and more 30 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy